Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.61 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | CSF1R | P07333 | 3/20 | 0.61 |
| ▸ | LYN | P07948 | 3/20 | 0.61 |
| ▸ | FLT1 | P17948 | 3/20 | 0.61 |
| ▸ | FLT4 | P35916 | 3/20 | 0.61 |
| ▸ | BLK | P51451 | 3/20 | 0.61 |
| ▸ | FYN | P06241 | 2/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.61 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
| ▸ | INSR | P06213 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858043 | 0.90 | NTRK1 (0.58) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL3846445 | 0.88 | KIT (0.66) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL3852682 | 0.88 | KIT (0.66) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL13873276 | 0.86 | KIT (0.61) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL13873329 | 0.85 | KIT (0.60) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL3846478 | 0.84 | CSF1R (0.64) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL3842232 | 0.84 | KIT (0.70) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL3847364 | 0.84 | KIT (0.65) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL13872993 | 0.83 | CSF1R (0.62) | KITLCKCSF1RLYNFLT1 | |
| SCHEMBL13872995 | 0.81 | DYRK3 (0.57) | KITLCKCSF1RLYNFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | claimed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | claimed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | claimed |
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2042500-A1 | N-[4-(1-H-pyrazolo[3,4-c]pyridin-4-yl)phenyl]-N'-[(hetero)aryl]-urea compounds, pharmaceutical compositions comprising them, their preparation and their use as Tie2-kinase inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | BAYER SCHERING PHARMA AG (DE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | KIT 4090/4885LCK 2085/4885CSF1R 867/4885 |
| US-20090062273-A1 | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. | KDR, FLT4, TIE1 | KIT 93/4885LCK 794/4885CSF1R 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.